More on TRUFF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.02 |
|
|||
| Open | $0.03 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.03 | ||||
| Day Low | $0.02 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 18,065 | ||||
- Rhelion unit signs psilocybin supply deal with Dutch research center
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
- Rhelion unit signs USC supply deal for psilocybin drug candidate
- Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
- Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic
- Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
- Rhelion Life Sciences Reports First Quarter 2027 Results
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate
Entities mentioned with TRUFF
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Bitcoin | View Related Stories »
- Twitter | View Related Stories »
- Show More...
